Beihai Kangcheng’s Velaglucerase β for Injection is Approved for Marketing in China
May 21, 2025
Source: drugdu
123
Beihai Kangcheng announced that its independently developed injectable velaglucerase beta (Gorinin, CAN103) has been approved for marketing by the China National Medical Products Administration on May 15, 2025 for the treatment of type I and type III Gaucher disease.
Gaucher disease is an autosomal recessive genetic disease caused by a deficiency of glucocerebrosidase, which leads to the accumulation of glucocerebroside in the body and causes a variety of symptoms. Gorenin is the first independently developed long-term enzyme replacement therapy in China suitable for adolescents aged 12 years and above and adults with type I and type III Gaucher disease.
https://finance.eastmoney.com/a/202505203409423342.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Bedaquiline Fumarate API Approved for Marketing, Enriching Anti-TB Drug Product Line July 25, 2025
- Huadong Medicine’s subsidiary’s Caspofungin Acetate for Injection approved by the U.S. FDA July 25, 2025
- Good news from AstraZeneca July 25, 2025
- A breakthrough in the cure of hepatitis B is in sight, and the share prices of leading pharmaceutical companies have doubled July 25, 2025
- A new hotspot in the innovative drug market July 25, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
